Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study

BACKGROUND: Regorafenib improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here, we report the treatment patterns of regorafenib in the third- or late-line setting for mCRC in four centers in China. PATIENTS AND METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Donghao, Liu, Yu, Tang, Wentao, Xu, Lingsha, Liu, Tianyu, Jiang, Yudong, Zhou, Shizhao, Qin, Xiaorui, Li, Jisheng, Zhao, Jiemin, Ye, Lechi, Chang, Wenju, Xu, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007238/
https://www.ncbi.nlm.nih.gov/pubmed/35433423
http://dx.doi.org/10.3389/fonc.2022.838870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007238/
https://www.ncbi.nlm.nih.gov/pubmed/35433423
http://dx.doi.org/10.3389/fonc.2022.838870

Ejemplares similares